Obesity drugs may spur licensing, distribution deals for Indian drugmakers after patent expires

“…distribution will be very difficult as there is a huge population in many markets, not just in India. Therefore, companies with local distribution/marketing presence will be preferred in this local market,” said Shrikant Akolkar, pharma analyst from Nuvama. Mint. “As we get closer to March 2026 (for India) when the product’s patent expires, I think we can expect more deals.”